|
Using the Serum Phosphoproteome of Migraine Patients as a Theragnostic
Biomarkers for neurological disease are lacking. Preliminary data, using an in vitro model of the blood brain barrier has suggested that serum release of tight junction proteins and the associated phosphoproteome may have utility as a biomarker for headache presence (diagnostic), such as migraine, and in therapeutic effect (theragnostic). This invention...
Published: 1/23/2024
|
Inventor(s): Tally Largent-Milnes, Jared Wahl
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios
|
|
Targeting 2AG Degradation for Headache
2-arachydonyl glycerol (2-AG) is a known endocannabinoid and a precursor compound for the generation of inflammatory mediators such as prostaglandins (PGs). This technology will enhance 2-AG levels and reduce PGs inhibiting enzymatic degradation. Several known compounds that work as inhibitors have been tested against the MAGL and ABHD6. The inventors...
Published: 11/16/2023
|
Inventor(s): Tally Largent-Milnes, Erika Liktor-Busa, Todd Vanderah, Nephi Stella
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics
|
|
Targeted Therapy for Itch
TMEM184B is a relatively uncharacterized 7-pass transmembrane protein that is a member of the Transporter-Opsin-GPCR (TOG) superfamily of proteins. It was discovered that over-expression of TMEM184B caused a reduction in scratching in response to interleukin-31 (Il-31) exposure. This was surprising given previous studies had shown that knock-out of...
Published: 3/12/2024
|
Inventor(s): Martha Bhattacharya, Tally Largent-Milnes
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Healthcare Portfolios > Dermatology, Technology Classifications > Life Sciences > Therapeutics
|
